Harnessing Next Generation Digital Pathology to Advance Biomarker Discovery Using New Technologies & Tools
Time: 11:40 am
day: Day 1 Track A AM
Details:
- Immune oncology therapies work through complex mechanisms requiring coordinated responses involving multiple classes of cells and activation states over time. The identification of biomarkers to inform drug development, clinical trials, and selection of patients in the clinic cannot be done as it has been in the past
- Emerging tools and techniques have dramatically altered the scale and complexity of spatial biology data, requiring new approaches to image and data analysis and opening new avenues of possibility in disease diagnosis and classification of patients. Furthermore, increasing plex of markers (100s-1000s), improving resolution (cellular and subcellular), and genomic, transcriptional, and protein level data are on millions of cells per study require a systematic, scalable, and explainable approach to panel development, pressure testing, validation, longitudinal stability testing, and image and data analysis
- Recent advancements in digital pathology and address the advantages and liabilities of a bottom-up vs a top-down approach in the integration of complexity and scale of data
